The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday.
In morning trade, the biotech companyâs shares are up a further 14% to a multi-year high of $11.36.
This means the ASX 300 share has now risen a whopping 48% over the last three sessions.
As you can see below, this has driven the Neuren share price almost 200% higher since this time last year.
Why is this ASX 300 share rocketing this week?
Investors have been buying this ASX 300 share after its treatment for Rettâs Syndrome was granted US FDA approval.
This is the first and only approved treatment for Rett Syndrome, which is a rare genetic neurological and developmental disorder that affects the way the brain develops.
The company has a deal in place with its partner Acadia Pharmaceuticals (NASDAQ: ACAD) that could result in significant revenue generation.
This includes royalties of up to 15% of net sales above US$750 million and sales milestone payments of up to US$350 million on total sales above US$1 billion in a calendar year.
Can its shares keep rising?
The good news is that Bell Potter believes the Neuren share price can keep rising even after its stellar gains this week.
This morning, the broker has retained its speculative buy rating with an improved price target of $13.67. This suggests that the ASX 300 share could rise a further 20% from current levels.
Bell Potter commented:
This is a huge success for the company, and we now expect income from trofinetide to come in at up to A$104m plus royalties in 2023. The next potential milestone payment to Neuren would be US$40m (A$61m at an assumed exchange rate of 0.65), payable following the first commercial sale of trofinetide in the United States.
Subsequently, Neuren is eligible to receive double-digit percentage royalties on net sales of trofinetide in North America, plus milestone payments of up to US$350m (A$538m) on achievement of a series of four thresholds of total annual net sales.
The post This ASX 300 healthcare stock is up 48% in 3 days. Broker says buy appeared first on The Motley Fool Australia.
Should you invest $1,000 in Neuren Pharmaceuticals Limited right now?
Before you consider Neuren Pharmaceuticals Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuren Pharmaceuticals Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of March 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Why Kingsgate, Neuren, Newcrest, and Pushpay shares are rising today
- Why Neuren, Northern Star, Race Oncology, and Westgold shares are storming higher
- Guess which ASX All Ords stock is rocketing 27% on a new FDA approval
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/STGljFd
Stock Pick 